Evidence map›Paper›PMID 35321944›Full record

ArticleAging2022

Construction and evaluation of a nomogram for predicting survival in patients with lung cancer.

Jin Ouyang, Zhijian Hu, Jianlin Tong, Yong Yang, Juan Wang, Xi Chen, Ting Luo, Shiqun Yu, Xin Wang, Shaoxin Huang

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Co‑expression ofOncology letters · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jin OuyangLaboratory of Precision Preventive Medicine, Medical School, Jiujiang University, Jiujiang, Jiangxi 332000, PR China.
Zhijian HuLaboratory Department, Jiujiang University Clinical Medical College, Jiujiang University Hospital, Jiujiang, Jiangxi 332000, PR China.
Jianlin TongLaboratory Department, Jiujiang University Clinical Medical College, Jiujiang University Hospital, Jiujiang, Jiangxi 332000, PR China.
Yong YangSpecAlly Life Technology Co. Ltd., Wuhan, Hubei 430075, PR China.
Juan WangSpecAlly Life Technology Co. Ltd., Wuhan, Hubei 430075, PR China.
Xi ChenSpecAlly Life Technology Co. Ltd., Wuhan, Hubei 430075, PR China.
Ting LuoLaboratory of Precision Preventive Medicine, Medical School, Jiujiang University, Jiujiang, Jiangxi 332000, PR China.
Shiqun YuLaboratory of Precision Preventive Medicine, Medical School, Jiujiang University, Jiujiang, Jiangxi 332000, PR China.
Xin WangLaboratory of Precision Preventive Medicine, Medical School, Jiujiang University, Jiujiang, Jiangxi 332000, PR China.
Shaoxin HuangLaboratory of Precision Preventive Medicine, Medical School, Jiujiang University, Jiujiang, Jiangxi 332000, PR China.
Jiujiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is a heterogeneous disease with a severe disease burden. Because the prognosis of patients with lung cancer varies, it is critical to identify effective biomarkers for prognosis prediction.

methodsA total of 2325 lung cancer patients were integrated into four independent sets (training set, validation set I, II and III) after removing batch effects in our study. We applied the microarray data algorithm to screen the differentially expressed genes in the training set. The most robust markers for prognosis were identified using the LASSO-Cox regression model, which was then used to create a Cox model and nomogram.

resultsThrough LASSO and multivariate Cox regression analysis, eight genes were identified as prognosis-associated hub genes, followed by the creation of prognosis-associated risk scores (PRS). The results of the Kaplan-Meier analysis in the three validation sets demonstrate the good predictive performance of PRS, with hazard ratios of 2.38 (95% confidence interval (CI), 1.61-3.53) in the validation set I, 1.35 (95% CI, 1.06-1.71) in the validation set II, and 2.71 (95% CI, 1.77-4.18) in the validation set III. Additionally, the PRS demonstrated superior survival prediction in subgroups by age, gender, p-stage, and histologic type (

conclusionsIn this study, we developed a PRS signature to help predict the survival of lung cancer. By combining it with clinical risk factors, a nomogram was established to quantify the individual risk assessments.

Indexed as

Lung NeoplasmsNomogramsHumansKaplan-Meier EstimatePrognosisProportional Hazards Modelsgene expression omnibuslung cancernomogramprognosisrisk score

Identifiers

PMID35321944
PMCPMC9004553
OpenAlexW4220930795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.